On a mini hiring spree, CRO Altasciences nabs ex-Charles River exec

Canadian pharmaceuticals
Canadian CRO Altasciences also added a new chief scientific officer just last month. (Shutterstock)

Just a month ago, Altasciences grabbed CRO veteran Beatrice Setnik, Ph.D., as its new chief scientific officer; now, it’s at it again.

The Canadian biopharma services company said it has hired Lynne LeSauteur, Ph.D., as its vice president of immunochemistry and immunology.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

LeSauteur comes out of the Human Health Therapeutics Research Center at the National Research Council of Canada where she helped discover, biomanufacture and characterize new biologics alongside life sciences companies.

RELATED: Syneos Health exec jumps ship to Canadian CRO Altasciences

Before this, she served a stint at fellow CRO Charles River Labs, where she established its immunology department.

Marie-Hélène Raigneau, EVP of research services at Altasciences, said: “We are extremely pleased to welcome Lynne to the team at Altasciences. The breadth of her experience in both preclinical and clinical drug development, including her in-depth knowledge of immunotoxicology, immunogenicity, immunoassays, molecular biology, and biomarkers, will continue to enhance scientific guidance to our growing base of small- to mid-size clients.”

Suggested Articles

Researchers at DeepMind believe they’ve cracked the code with a computer model that can translate an amino acid chain into a 3D protein structure.

A computer model developed by MGH researchers identified signs in breast cancer images that could predict a woman’s chances of developing the disease.

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.